Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
Study sponsor: Allogene Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-02-20Actual
Enrollment · participants2Actual
Source updated2026-03-02Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.